Literature DB >> 28306543

Peripheral levels of BDNF and opiate-use disorder: literature review and update.

Raul Felipe Palma-Álvarez1, Elena Ros-Cucurull1, Kristopher Amaro-Hosey1, Laia Rodriguez-Cintas1, Lara Grau-López1, Margarida Corominas-Roso1, Cristina Sánchez-Mora1, Carlos Roncero1.   

Abstract

Several neurobiological factors are related to opiate-use disorder (OUD), and among them, neurotrophins have a relevant role. Brain-derived neurotrophic factor (BDNF) is a central neurotrophin involved in many neuronal processes, and it has been related to several psychiatric diseases and addictive disorders. BDNF can be measured in plasma and serum; its levels may reflect BDNF concentrations in the central nervous system (CNS) and, indirectly, CNS processes. Hence, peripheral BDNF could be a biomarker in clinical practice. This manuscript explores the findings about peripheral BDNF and OUD in humans. Opiates induce neurotoxicity in the CNS, which may be correlated with modifications in BDNF expression. Thus, basal levels of peripheral BDNF in OUD patients may be altered, which could be modified with abstinence. Also, opiates may modify epigenetic processes that may be associated with peripheral concentrations of BDNF, and in this line, withdrawal could reflect recovering processes in the CNS. Additionally, treatment modifies the peripheral concentrations of BDNF, but the clinical implications of those changes are yet not elucidated. No specific conclusion can be performed and more investigation in this area is necessary to elucidate the real potential of peripheral BDNF as a biomarker.

Entities:  

Keywords:  BDNF; biomarker; heroin; opiate; opiate-use disorder

Mesh:

Substances:

Year:  2017        PMID: 28306543     DOI: 10.1515/revneuro-2016-0078

Source DB:  PubMed          Journal:  Rev Neurosci        ISSN: 0334-1763            Impact factor:   4.353


  6 in total

Review 1.  Aerobic exercise as a promising nonpharmacological therapy for the treatment of substance use disorders.

Authors:  Gigliola Marrero-Cristobal; Ursula Gelpi-Dominguez; Roberto Morales-Silva; John Alvarado-Torres; Joshua Perez-Torres; Yobet Perez-Perez; Marian Sepulveda-Orengo
Journal:  J Neurosci Res       Date:  2021-12-01       Impact factor: 4.433

2.  Investigating the link between serum concentrations of brain-derived neurotrophic factor and behavioral measures in anxious alcohol-dependent individuals.

Authors:  Jeanelle Portelli; Mehdi Farokhnia; Sara L Deschaine; Jillian T Battista; Mary R Lee; Xiaobai Li; Dorit Ron; Lorenzo Leggio
Journal:  Alcohol       Date:  2020-08-13       Impact factor: 2.405

3.  Comparing the Efficacy of Anodal, Cathodal, and Sham Transcranial Direct Current Stimulation on Brain-Derived Neurotrophic Factor and Psychological Symptoms in Opioid-Addicted Patients.

Authors:  Zakaria Eskandari; Mohsen Dadashi; Hossin Mostafavi; Alireza Armani Kia; Reza Pirzeh
Journal:  Basic Clin Neurosci       Date:  2019-11-01

4.  Clustering suicidal phenotypes and genetic associations with brain-derived neurotrophic factor in patients with substance use disorders.

Authors:  Romain Icick; Vanessa Bloch; Nathalie Prince; Emily Karsinti; Jean-Pierre Lépine; Jean-Louis Laplanche; Stéphane Mouly; Cynthia Marie-Claire; Georges Brousse; Frank Bellivier; Florence Vorspan
Journal:  Transl Psychiatry       Date:  2021-01-21       Impact factor: 6.222

5.  Plasma Brain-Derived Neurotrophic Factor Levels in Newborn Infants with Neonatal Abstinence Syndrome.

Authors:  Lochan Subedi; Hong Huang; Amrita Pant; Philip M Westgate; Henrietta S Bada; John A Bauer; Peter J Giannone; Thitinart Sithisarn
Journal:  Front Pediatr       Date:  2017-11-03       Impact factor: 3.418

6.  Evaluation of serum levels of neurotrophin 4 and brain-derived nerve growth factor in uremic pruritus patients.

Authors:  Neveen E Sorour; Fatma M Elesawy; Hala A Tabl; Mohammed E Ibrahim; Essam M Akl
Journal:  Clin Cosmet Investig Dermatol       Date:  2019-02-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.